Treatment of peripheral T-cell lymphomas

Peripheral T-cell lymphomas (PTCLs) are rare neoplasms that recently have been the subject of much research into their complex pathophysiology. PTCLs a heterogeneous group tumors consisting nodal and extranodal leukemic cutaneous neoplasms. associated with biology arduous pathology which is currently being studied. According to this research, pathophysiology can be divided intrinsic extrinsic mechanisms. Among mechanisms, scientists described JAK-STAT pathway deregulation, as well different somatic mutations including RB1, PTEN, TP53 structural changes receptors. Also, there scientific papers correlate Epstein-Bárr virus or human lymphotropic type 1 infections occurrence neoplasm. most likely develop in Asian African populations. Due poor clinical outcomes, PTCL treatment intense research. As result that, new drugs approved by Food Drug Administration for use among patients refractory PTCL: pralatrexate, an antifolate drug; romidepsin, belinostat, inhibitor histone deacetylase, brentuximab vedotin, CD30 antibody. trials mogamulizumab carried out treatment. In addition this, lenalidomide, substance regulates immune system has shown antineoplastic effect several hematological studies, could possibly considered